Pfizer and Roche Holdings, two powerful pharmaceutical companies, are developing weight loss drugs, potentially disrupting the market dominated by Novo Nordisk and Eli Lilly. Pfizer's danuglipron is in phase 1 clinical trials, but previous studies showed high patient discontinuation rates and limited efficacy. Roche's CT-996, also in phase 1, has shown promising results.